The pharmaceutical industry has recognized that non-adherence results in significant costs to the healthcare system.  According to recent studies and reports, one in particular conducted by Capgemeni and HealthPrize, determined a loss of $637 billion in potential annual sales including $250 billion (40%) in the U.S. alone.  This same study was first conducted by Capgemeni and HealthPrize in 2012 when it was found that $564 billion was lost in global annual revenue including $188 billion in the U.S., reflecting an increase of 13% and 33%, respectively.  Oftentimes non-adherence focuses on increased medical costs to the healthcare system and health outcomes for patients, which is estimated at $300 billion annually.  Needless to say pharma companies have initiated various partnerships, and programs that incorporate strategies to improve adherence.
 
This session will present Adherium’s validated digital health platform, which focuses on improved outcomes in disease management of asthma and COPD.  Join us in learning about the patient experience, the provider viewpoint, and the foundation supporting the complete Smartinhaler™ solution.